Evidence-based medicine and myocardial protection where is the evidence?

被引:25
作者
Ferguson, Z. G. [1 ]
Yarborough, D. E. [1 ]
Jarvis, B. L. [1 ]
Sistino, J. J. [1 ]
机构
[1] Med Univ S Carolina, Charleston, SC 29425 USA
来源
PERFUSION-UK | 2015年 / 30卷 / 05期
关键词
cardioplegia; systematic review; myocardial protection; HISTIDINE-TRYPTOPHAN-KETOGLUTARATE; HTK CARDIOPLEGIC SOLUTION; COLD-BLOOD-CARDIOPLEGIA; CARDIAC-SURGERY; CRYSTALLOID CARDIOPLEGIA; MULTIDOSE CARDIOPLEGIA; HEART-SURGERY; BYPASS-SURGERY; SUPERIOR; BRETSCHNEIDER;
D O I
10.1177/0267659114551856
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Myocardial protection with cardioplegia is an integral component of most cardiac surgical procedures, providing protection of the heart by limiting metabolic activity and increasing the myocardium's capacity to withstand ischemia for prolonged periods of time. Cardioplegia has greatly affected the landscape of cardiothoracic surgery since its introduction in the 1960s, but, to this day, there continues to be a debate over what the ideal cardioplegic solution should be. The goal of this analysis is to describe current practices in cardioplegia and to point out the lack of quality human research and subsequent publications that prevent best practices from being utilized. Methods: This study is a systematic review of journal publications pertaining to the composition of commonly used cardioplegic solutions. Four main types of cardioplegia were assessed to give a narrower field of examination; specifically, microplegia, del Nido, Custodiol HTK, and 4:1 blood cardioplegia. Other combinations of cardioplegia, including St. Thomas's Solution and the University of Wisconsin (UW) Solution, were considered when applicable according to the context of the publication being reviewed. Factors being assessed consisted of scientific validity, nature of the test subject (isolated organ vs. animal vs. human studies), experimental setup (retrospective trials vs. randomized clinical trials) and patient outcomes. Results: There are very few randomized clinical trials with human subjects comparing commonly used cardioplegic solutions. Numerous retrospective studies exist, but often show similar intraoperative and postoperative outcomes between the solutions. Some solutions, del Nido cardioplegia in particular, were found to have few or no significant human trials to back the rigor required in such a highly specialized field as cardiovascular surgery. A wide variation in the types of surgeries and primary outcomes were included in the publications, so it is difficult to perform an accurate systematic review of the topic. Conclusion: Uniform variables among different studies would be preferable for analysis of this topic; thus, it is the researchers' recommendation that the collection of multicenter data be undertaken in order to more fully answer this research question. Comparative effectiveness studies to associate commonly used solutions are needed. Without this research, surgeon preference remains the primary determining factor for deciding which cardioplegic solution to use. Cardioplegia selection should rely more on higher scientific research, using evidenced-based medicine and ranking of clinical studies.
引用
收藏
页码:415 / 422
页数:8
相关论文
共 48 条
[1]  
Albacker Turki B, 2009, Interact Cardiovasc Thorac Surg, V9, P56, DOI 10.1510/icvts.2009.204990
[2]   Microplegia During Coronary Artery Bypass Grafting Was Associated With Less Low Cardiac Output Syndrome: A Propensity-Matched Comparison [J].
Algarni, Khaled D. ;
Weisel, Richard D. ;
Caldarone, Christopher A. ;
Maganti, Manjula ;
Tsang, Katherine ;
Yau, Terrence M. .
ANNALS OF THORACIC SURGERY, 2013, 95 (05) :1532-1538
[3]   Myocardial metabolism is better preserved after blood cardioplegia in infants [J].
Åmark, K ;
Berggren, H ;
Björk, K ;
Ekroth, A ;
Ekroth, R ;
Nilsson, K ;
Sunnegårdh, J .
ANNALS OF THORACIC SURGERY, 2006, 82 (01) :172-178
[4]   Blood cardioplegia provides superior protection in infant cardiac surgery [J].
Åmark, K ;
Berggren, H ;
Björk, K ;
Ekroth, A ;
Ekroth, R ;
Nilsson, K ;
Sunnegårdh, J .
ANNALS OF THORACIC SURGERY, 2005, 80 (03) :989-994
[5]  
[Anonymous], NY TIMES
[6]   CLINICAL-EVALUATION OF HYPOTHERMIC VENTRICULAR-FIBRILLATION, MULTIDOSE BLOOD CARDIOPLEGIA, AND SINGLE-DOSE BRETSCHNEIDER CARDIOPLEGIA IN CORONARY SURGERY [J].
BEYERSDORF, F ;
KRAUSE, E ;
SARAI, K ;
SIEBER, B ;
DEUTSCHLANDER, N ;
ZIMMER, G ;
MAINKA, L ;
PROBST, S ;
ZEGELMAN, M ;
SCHNEIDER, W ;
SATTER, P .
THORACIC AND CARDIOVASCULAR SURGEON, 1990, 38 (01) :20-29
[7]   Cold Histidine-Tryptophan-Ketoglutarate Solution and Repeated Oxygenated Warm Blood Cardioplegia in Neonates With Arterial Switch Operation [J].
Bojan, Mirela ;
Peperstraete, Harlinde ;
Lilot, Marc ;
Tourneur, Laurent ;
Vouhe, Pascal ;
Pouard, Philippe .
ANNALS OF THORACIC SURGERY, 2013, 95 (04) :1390-1396
[8]   One single dose of histidine-tryptophan-ketoglutarate solution gives equally good myocardial protection in elective mitral valve surgery as repetitive cold blood cardioplegia: A prospective randomized study [J].
Braathen, Bjorn ;
Jeppsson, Anders ;
Schersten, Henrik ;
Hagen, Ole M. ;
Vengen, Oystein ;
Rexius, Helena ;
Lepore, Vincenzo ;
Tonnessen, Theis .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2011, 141 (04) :995-1001
[9]   Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients [J].
Careaga, G ;
Salazar, D ;
Téllez, S ;
Sánchez, O ;
Borrayo, G ;
Argüero, R .
ARCHIVES OF MEDICAL RESEARCH, 2001, 32 (04) :296-299
[10]   Single dose myocardial protection technique utilizing del Nido cardioplegia solution during congenital heart surgery procedures [J].
Charette, K. ;
Gerrah, R. ;
Quaegebeur, J. ;
Chen, J. ;
Riley, D. ;
Mongero, L. ;
Corda, R. ;
Bacha, E. .
PERFUSION-UK, 2012, 27 (02) :98-102